Gülker H, Heuer H, Frenking B, Haverkamp W, Hindricks G, Bozek B, Bremkes C, Asche K D, Witthöft D
Medizinische Universitätsklinik Münster.
Z Kardiol. 1988 Sep;77(9):587-94.
Barucainide is a new class Ib-antiarrhythmic compound which causes a reduction of the upstroke velocity and shortens the duration of the action potential in a dose-dependent fashion. The electrophysiological, hemodynamic and antiarrhythmic effects of the new drug were analyzed in experimental and clinical investigations. The results show that barucainide, in a dose range varying between 0.125-4.0 mg/kg i.v. fails to exert any significant effect on cardiac conduction and refractory times, heart rate, arterial blood pressure, cardiac output and left ventricular contractility. In a standardized animal model of ventricular arrhythmia, barucainide proved to be superior to lidocaine with respect to its antiarrhythmic potency. In a group of patients displaying chronic, otherwise therapy-resistant ventricular arrhythmias, the drug was effective in the majority of cases. Tolerance was excellent over a maximum observation period of 18 months. According to our first experimental and clinical observations, further testing of barucainide appears promising. The drug may be of particular value for treatment of ventricular arrhythmias in cases with left ventricular dysfunction, heart failure and severe conduction disturbances.
巴鲁卡胺是一种新型I b类抗心律失常化合物，它能以剂量依赖的方式降低动作电位的上升速度并缩短动作电位时程。在实验和临床研究中分析了这种新药的电生理、血液动力学和抗心律失常作用。结果表明，静脉注射剂量在0.125 - 4.0毫克/千克之间的巴鲁卡胺，对心脏传导、不应期、心率、动脉血压、心输出量和左心室收缩性均无显著影响。在一个标准化的室性心律失常动物模型中，巴鲁卡胺在抗心律失常效力方面被证明优于利多卡因。在一组表现为慢性、对其他治疗有抵抗的室性心律失常患者中，该药在大多数病例中有效。在长达18个月的最大观察期内耐受性良好。根据我们最初的实验和临床观察，巴鲁卡胺的进一步试验似乎很有前景。该药对于治疗伴有左心室功能障碍、心力衰竭和严重传导障碍的室性心律失常可能具有特殊价值。
